“We are absolutely thrilled and grateful for this achievement. Securing a patent in Japan, one of the world’s most advanced markets for medical technology, is once again a strong validation of our innovation and potential. The fact that it comes so soon after our Australian patent makes it even more special,” says Jean Lycke, Project Manager at Mucocort AB.
Japan is a strategically important market for medical innovations, and this patent opens up opportunities for collaborations with leading medtech companies in the region. It represents another crucial step in Mucocort AB’s international expansion, bringing M045A closer to patients worldwide.
Mucocort is part of and receives business support from Umeå Biotech Incubator.